Our securities attorneys are investigating claims on behalf of investors of SteadyMed Ltd. (NASDAQ: STDY) regarding possible violations of federal securities laws following the FDA’s refusal to review the company’s new drug application for Trevyent.

SteadyMed Stock Losses?

If you acquired shares in SteadyMed Ltd. and would like to learn more about your legal rights, call or message us to speak privately with a securities attorney.

  • This field is for validation purposes and should be left unchanged.

(800) 254-9493

News of FDA Refusal to File Letter Prompts Stock Drop

On August 31, 2017, SteadyMed announced that it had received a Refusal to File letter from the FDA regarding the company’s New Drug Application for Trevyent, a treatment for pulmonary arterial hypertension. Specifically, the FDA determined, based on a preliminary review of the New Drug Application, that it was not complete enough to permit a substantive review. According to SteadyMed, the FDA requested additional information on certain device specifications and performance testing as well as additional design verification and validation testing on the final Trevyent product.

Following this news, SteadyMed’s share price plummeted by more than 44% in intraday trading, to ultimately close down more than 35% at $3.80 on August 31, 2017.

Our Reputation for Excellence

Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for four consecutive years.